Zuogui Wan modulates macrophage polarization and promotes osteogenic differentiation through regulation of CD51-positive bone marrow mesenchymal stem cells.
Animals
Mesenchymal Stem Cells
/ metabolism
Osteogenesis
/ drug effects
Cell Differentiation
/ drug effects
Drugs, Chinese Herbal
/ pharmacology
Female
Macrophages
/ metabolism
Rats
Ovariectomy
Osteoporosis, Postmenopausal
/ metabolism
Rats, Sprague-Dawley
Disease Models, Animal
X-Ray Microtomography
Osteoblasts
/ metabolism
Humans
Osteoclasts
/ metabolism
Bone Resorption
/ metabolism
Bone marrow mesenchymal stem cells (BMSCs)
CD51
Macrophage polarization
Postmenopausal osteoporosis (PMOP)
Zuogui Wan (ZGW)
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
30 10 2024
30 10 2024
Historique:
received:
28
03
2024
accepted:
23
10
2024
medline:
31
10
2024
pubmed:
31
10
2024
entrez:
31
10
2024
Statut:
epublish
Résumé
Background Zuogui Wan (ZGW) is a traditional herbal formula used to treat chronic kidney and bone diseases. Previous research has shown that ZGW slows down the aging process of bone marrow mesenchymal stem cells (BMSCs) and improves bone metabolism. However, its role in treating postmenopausal osteoporosis (PMOP) has not yet been fully investigated. Therefore, we investigated the therapeutic effects of ZGW and its potential mechanisms in an ovariectomy (OVX)-induced osteoporosis rat model. Results We observed significant improvements in bone loss and the osteoporotic phenotype in OVX rats treated with ZGW. These findings were confirmed with micro-computed tomography (micro-CT) and histomorphological analysis. We also discovered that ZGW reversed the macrophage imbalance, which in turn inhibited osteoclast differentiation and bone resorption. Furthermore, RNA-Seq results revealed the active expression of CD51 in BMSCs before and after ZGW therapy, which is associated with macrophage polarization and osteoblastic differentiation. The results also showed that ZGW decreased CD51 + BMSCs levels, which is closely related to the inhibition of osteoblast differentiation and promotion of osteoclast resorption. Conclusions Our study demonstrated that ZGW may improve postmenopausal osteoporosis by restoring macrophage polarization and down-regulating CD51 + BMSCs. In addition, ZGW promoted osteoblast formation and inhibited osteoclast resorption.
Identifiants
pubmed: 39478130
doi: 10.1038/s41598-024-77590-5
pii: 10.1038/s41598-024-77590-5
doi:
Substances chimiques
Drugs, Chinese Herbal
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
26130Subventions
Organisme : National Natural Science Foundation of China
ID : No. 82174226
Organisme : Xinglin talent Foundation of Chengdu University of TCM
ID : XSGG2020002
Informations de copyright
© 2024. The Author(s).
Références
Li, J., Chen, X., Lu, L. & Yu, X. The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis. Cytokine Growth Factor. Rev. 52, 88–98. https://doi.org/10.1016/j.cytogfr.2020.02.003 (2020).
doi: 10.1016/j.cytogfr.2020.02.003
pubmed: 32081538
Zhu, X. et al. Risk factors of primary and recurrent fractures in postmenopausal osteoporotic Chinese patients: A retrospective analysis study. BMC Womens Health. 22, 465. https://doi.org/10.1186/s12905-022-02034-z (2022).
doi: 10.1186/s12905-022-02034-z
pubmed: 36404305
pmcid: 9677643
Zhu, H. et al. Associations between ERα/β gene polymorphisms and osteoporosis susceptibility and bone mineral density in postmenopausal women: a systematic review and meta-analysis. BMC Endocr. Disord. 18 https://doi.org/10.1186/s12902-018-0230-x (2018).
Qiu, Y. et al. Osteoporosis in postmenopausal women in this decade: a bibliometric assessment of current research and future hotspots. Arch. Osteoporos. 13, 121. https://doi.org/10.1007/s11657-018-0534-5 (2018).
Schacht, E., Dukas, L. & Richy, F. Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs. J. Musculoskelet. Neuronal Interact. 7, 174–184 (2007).
pubmed: 17627088
Choi, J. Y. Healthy bone tissue homeostasis. Exp. Mol. Med. 52, 1165. https://doi.org/10.1038/s12276-020-0472-3 (2020).
doi: 10.1038/s12276-020-0472-3
pubmed: 32788654
pmcid: 8080694
Kadomoto, S., Izumi, K. & Mizokami, A. Macrophage Polarity and Disease Control. Int. J. Mol. Sci. 23 https://doi.org/10.3390/ijms23010144 (2021).
Härkönen, P. L. & Väänänen, H. K. Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators. Ann. N Y Acad. Sci. 1089, 218–227. https://doi.org/10.1196/annals.1386.045 (2006).
Bolego, C., Cignarella, A., Staels, B. & Chinetti-Gbaguidi, G. Macrophage function and polarization in cardiovascular disease: a role of estrogen signaling? Arterioscler. Thromb. Vasc Biol. 33, 1127–1134. https://doi.org/10.1161/atvbaha.113.301328 (2013).
doi: 10.1161/atvbaha.113.301328
pubmed: 23640494
Yao, Y. et al. The Macrophage-Osteoclast Axis in Osteoimmunity and Osteo-Related Diseases. Front. Immunol. 12, 664871. https://doi.org/10.3389/fimmu.2021.664871 (2021).
doi: 10.3389/fimmu.2021.664871
pubmed: 33868316
pmcid: 8044404
Li, J. et al. An evaluation of the effects and safety of Zuogui pill for treating osteoporosis: Current evidence for an ancient Chinese herbal formula. Phytother Res. 35, 1754–1767. https://doi.org/10.1002/ptr.6908 (2021).
doi: 10.1002/ptr.6908
pubmed: 33089589
Tianqi, W. et al. Zuogui and Yougui pills improve perimenopausal syndrome regulation of apoptosis in mice. J. Tradit Chin. Med. 43, 474–483. https://doi.org/10.19852/j.cnki.jtcm.20220507.001 (2023).
doi: 10.19852/j.cnki.jtcm.20220507.001
pubmed: 37147748
Liu, H. et al. Zuogui Pill Attenuates Neuroinflammation and Improves Cognitive Function in Cerebral Ischemia Reperfusion-Injured Rats. Neuroimmunomodulation. 29, 143–150. https://doi.org/10.1159/000519010 (2022).
doi: 10.1159/000519010
pubmed: 34736255
Chen, G. et al. Efficacy and safety of Zuogui Pill in treating osteoporosis: Study protocol of a systematic review. Med. (Baltim). 98, e13936. https://doi.org/10.1097/md.0000000000013936 (2019).
doi: 10.1097/md.0000000000013936
Shi, T. et al. The Synergistic Effect of Zuogui Pill and Eldecalcitol on Improving Bone Mass and Osteogenesis in Type 2 Diabetic Osteoporosis. Med. (Kaunas). 59 https://doi.org/10.3390/medicina59081414 (2023).
Zhu, B. et al. Zuogui Wan ameliorates high glucose-induced podocyte apoptosis and improves diabetic nephropathy in db/db mice. Front. Pharmacol. 13, 991976. https://doi.org/10.3389/fphar.2022.991976 (2022).
doi: 10.3389/fphar.2022.991976
pubmed: 36386214
pmcid: 9663993
Liu, J. et al. Hyperoside Suppresses Renal Inflammation by Regulating Macrophage Polarization in Mice With Type 2 Diabetes Mellitus. Front. Immunol. 12, 733808. https://doi.org/10.3389/fimmu.2021.733808 (2021).
doi: 10.3389/fimmu.2021.733808
pubmed: 34925317
pmcid: 8678409
Hadjidakis, D. J. & Androulakis, I. I. Bone remodeling. Ann. N Y Acad. Sci. 1092, 385–396. https://doi.org/10.1196/annals.1365.035 (2006).
Pierce, J. L., Begun, D. L., Westendorf, J. J. & McGee-Lawrence, M. E. Defining osteoblast and adipocyte lineages in the bone marrow. Bone. 118, 2–7. https://doi.org/10.1016/j.bone.2018.05.019 (2019).
doi: 10.1016/j.bone.2018.05.019
pubmed: 29782940
Xie, Z. et al. Single-cell RNA sequencing analysis of human bone-marrow-derived mesenchymal stem cells and functional subpopulation identification. Exp. Mol. Med. 54, 483–492. https://doi.org/10.1038/s12276-022-00749-5 (2022).
doi: 10.1038/s12276-022-00749-5
pubmed: 35365767
pmcid: 9076886
Zhao, J. et al. Efficacy of Chinese patent medicine for primary osteoporosis: A network meta-analysis. Complement. Ther. Clin. Pract. 44, 101419. https://doi.org/10.1016/j.ctcp.2021.101419 (2021).
doi: 10.1016/j.ctcp.2021.101419
pubmed: 34049211
Qiu, J. et al. Comparative pharmacokinetic study of 5 active ingredients after oral administration of Zuogui Pill in osteoporotic rats with different syndrome types. Int. J. Anal. Chem. 2023, 1473878). https://doi.org/10.1155/2023/1473878 (2023).
Yin, H. et al. Zuogui Pill improves the dexamethasone-induced osteoporosis progression in zebrafish larvae. Biomed. Pharmacother. 97, 995–999. https://doi.org/10.1016/j.biopha.2017.11.029 (2018).
doi: 10.1016/j.biopha.2017.11.029
pubmed: 29136778
Taylor, R. et al. Osteoclast formation and function in pigmented villonodular synovitis. J. Pathol. 225, 151–156. https://doi.org/10.1002/path.2937 (2011).
doi: 10.1002/path.2937
pubmed: 21706481
Maggiani, F., Forsyth, R., Hogendoorn, P. C., Krenacs, T. & Athanasou, N. A. The immunophenotype of osteoclasts and macrophage polykaryons. J. Clin. Pathol. 64, 701–705. https://doi.org/10.1136/jcp.2011.090852 (2011).
Li, S. et al. Chlorogenic acid protects MSCs against oxidative stress by altering FOXO family genes and activating intrinsic pathway. Eur. J. Pharmacol. 674, 65–72. https://doi.org/10.1016/j.ejphar.2011.06.033 (2012).
doi: 10.1016/j.ejphar.2011.06.033
pubmed: 21749866
Yan, C. P. et al. β-ecdysterone enhanced bone regeneration through the BMP-2/SMAD/RUNX2/Osterix signaling pathway. Front. Cell. Dev. Biol. 10, 883228. https://doi.org/10.3389/fcell.2022.883228 (2022).
doi: 10.3389/fcell.2022.883228
pubmed: 35669516
pmcid: 9164109
Wei, Q. et al. Effect of hyperoside on osteoporosis in ovariectomized mice through estrogen receptor α/ITGβ3 signaling pathway. Eur. J. Pharmacol. 977, 176666. https://doi.org/10.1016/j.ejphar.2024.176666 (2024).
doi: 10.1016/j.ejphar.2024.176666
pubmed: 38797313
Xiao, J. et al. Morroniside Inhibits Inflammatory Bone Loss through the TRAF6-Mediated NF-κB/MAPK Signaling Pathway. Pharmaceuticals (Basel). 16 https://doi.org/10.3390/ph16101438 (2023).
Lv, F. et al. Toxicological safety evaluation of zengye granule through acute and 30-day toxicity studies in rats. J. Ethnopharmacol. 318, 116884. https://doi.org/10.1016/j.jep.2023.116884 (2024).
doi: 10.1016/j.jep.2023.116884
pubmed: 37453627
Muñoz, J., Akhavan, N. S., Mullins, A. P. & Arjmandi, B. H. Macrophage polarization and osteoporosis: A review. Nutrients 12. https://doi.org/10.3390/nu12102999 (2020).
Columbo, M. & Bochner, B. S. Human skin mast cells adhere to vitronectin via the alphavbeta3 integrin receptor (CD51/CD61). J. Allergy Clin. Immunol. 107, 554. https://doi.org/10.1067/mai.2001.113238 (2001).
doi: 10.1067/mai.2001.113238
pubmed: 11240961
Chen, P. et al. Characterization and differentiation of CD51(+) Stem Leydig cells in adult mouse testes. Mol. Cell. Endocrinol. 493, 110449. https://doi.org/10.1016/j.mce.2019.110449 (2019).
doi: 10.1016/j.mce.2019.110449
pubmed: 31102608
Pinho, S. et al. PDGFRα and CD51 mark human nestin + sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J. Exp. Med. 210, 1351–1367. https://doi.org/10.1084/jem.20122252 (2013).
doi: 10.1084/jem.20122252
pubmed: 23776077
pmcid: 3698522
Taylor, R. M. et al. CD14- mononuclear stromal cells support (CD14+) monocyte-osteoclast differentiation in aneurysmal bone cyst. Lab. Invest. 92, 600–605. https://doi.org/10.1038/labinvest.2012.5 (2012).
Kim, H. K. et al. Mevinolin enhances osteogenic genes (ALP, type I collagen and osteocalcin), CD44, CD47 and CD51 expression during osteogenic differentiation. Life Sci. 84, 290–295. https://doi.org/10.1016/j.lfs.2008.12.017 (2009).
doi: 10.1016/j.lfs.2008.12.017
pubmed: 19162043
Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27–30. https://doi.org/10.1093/nar/28.1.27 (2000).
doi: 10.1093/nar/28.1.27
pubmed: 10592173
pmcid: 102409